← All trials
NCT05087498
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2021
- Primary completion
- Dec 31, 2022
- Completion date
- Oct 30, 2023
- First posted
- Oct 21, 2021
- Last posted
- Oct 21, 2021
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Guangdong Women and Children HospitalLead sponsor
- Guangdong Women and Children HospitalReponsible party - principal investigator
- Guangdong Women and Children HospitalStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.